Form 4: Maze Therapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
Atul Dandekar, CSBO of Maze Therapeutics, Inc., reported multiple transactions in common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 12,500 Common Stock on September 1, 2026; holds 38,750 after (Direct).
- Option exercise/conversion: disposed of 12,500 Restricted Stock Units on September 1, 2026; holds 12,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Atul Dandekar — Officer (CSBO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 12,500 | — | — | 38,750 |
| 2026-09-01 | Option exercise/conversion | Restricted Stock Units | 12,500 | — | — | 12,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (12,500 shares) |
| 2026-09-01 | Option exercise/conversion (12,500 shares) |
Keywords
insider transaction, Form 4, MAZE, Maze Therapeutics, Inc., neutral, Atul Dandekar
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.